Search Within

Rachel Nicole Grisham

Formats
  1. Journal Article (80)
  2. Meeting Abstract (78)
  3. Review (9)
  4. Guidelines (3)
  5. Book Section (2)
  6. Editorial (2)
  7. Correspondence (1)
Groups
  1. Department of Medicine (175)
  2. GDMT, Medicine (175)
  3. Gynecologic Medicine Service (175)
  4. Gynecology Disease Management Team (175)
  5. Solid Tumor Oncology Division (175)
  6. Surgery (76)

More Groups

People
  1. Carol Aghajanian (87)
  2. Roisin O'Cearbhaill (68)
  3. Alexia Iasonos (63)
  4. Qin Zhou (56)
  5. Dennis Chi (52)
  6. Kara Long Roche (49)

More People

Years
  1. 2025 (13)
  2. 2024 (29)
  3. 2023 (26)
  4. 2022 (23)
  5. 2021 (12)
  6. 2020 (21)

More Years

Publications
  1. Gynecologic Oncology (49)
  2. Journal of Clinical Oncology (37)
  3. International Journal of Gynecological Cancer (28)
  4. Clinical Cancer Research (8)
  5. Cancer (7)
  6. Annals of Oncology (6)

More Publications

Publishers
  1. Elsevier Inc. (50)
  2. American Society of Clinical Oncology (42)
  3. Lippincott Williams & Wilkins (30)
  4. American Association for Cancer Research (10)
  5. Wiley Blackwell (8)
  6. Nature Publishing Group (6)

More Publishers

Results (175)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Germline and somatic tumor testing in epithelial ovarian cancer: ASCO guideline
    Guidelines

    Konstantinopoulos, P. A.; Norquist, B.; Lacchetti, C.; Armstrong, D.; Grisham, R. N.; Goodfellow, P. J.; Kohn, E. C.; Levine, D. A.; Liu, J. F.; Lu, K. H.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer
    Journal Article

    Cadoo, K. A.; Grisham, R. N.; O'Cearbhaill, R. E.; Boucicaut, N. N.; Henson, M.; Iasonos, A.; Zhou, Q.; Sarasohn, D. M.; Gallagher, J.; Kravetz, S.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Low-grade serous ovarian cancer: State of the science
    Review

    Slomovitz, B.; Gourley, C.; Carey, M. S.; Malpica, A.; Shih, I. M.; Huntsman, D.; Fader, A. N.; Grisham, R. N.; Schlumbrecht, M.; Sun, C. C.; more...
    Gynecologic Oncology (2020)

    Fulltext@MSK | Save
  • Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
    Journal Article

    Rubinstein, M. M.; Hyman, D. M.; Caird, I.; Won, H.; Soldan, K.; Seier, K.; Iasonos, A.; Tew, W. P.; O’Cearbhaill, R. E.; Grisham, R. N.; more...
    Cancer (2020)

    Fulltext@MSK | Save
  • A phase 2 study of TPIV200/ huFR-1 (a multi-epitope folate receptor alpha vaccine) in combination with durvalumab in patients with platinum resistant ovarian cancer
    Meeting Abstract

    Zamarin, D.; Yeku, O.; O'Cearbhaill, R. E.; Cadoo, K. A.; Gallagher, J.; Kravetz, S.; McDonnell, A.; Troso-Sandoval, T.; Sabbatini, P.; Lichtman, S.; more...
    Clinical Cancer Research (2019)

    Fulltext@MSK | Save
  • Activity of M3814, an oral DNA-PK inhibitor, in combination with topoisomerase II inhibitors in ovarian cancer models
    Journal Article

    Wise, H. C.; Iyer, G. V.; Moore, K.; Temkin, S. M.; Gordon, S.; Aghajanian, C.; Grisham, R. N.
    Scientific Reports (2019)

    Fulltext@MSK | Save
  • Phase II study of enzalutamide in androgen receptor positive (AR+) recurrent ovarian cancer: Final results
    Meeting Abstract

    Grisham, R.; Giri, D.; Henson, M.; Iasonos, A.; Zhou, Q.; McDonnell, A.; Girshman, J.; O'Cearbhaill, R.; Zamarin, D.; Aghajanian, C.
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • MILO/ENGOT-ov11: Phase-3 study of binimetinib versus physician's choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
    Meeting Abstract

    Grisham, R.; Monk, B. J.; Banerjee, S.; Coleman, R. L.; Oza, A. M.; Oehler, M. K.; Kalbacher, E.; Mirza Raza, M.; del Campo, J. M.; Marth, C.; more...
    International Journal of Gynecological Cancer (2019)

    Fulltext@MSK | Save
  • Randomized, phase Ib/II study of M6620 + avelumab + carboplatin vs standard care (sc) in patients (pts) with platinum-sensitive poly (ADP-ribose) polymerase inhibitor-(PARPi)-resistant ovarian cancer
    Meeting Abstract

    Banerjee, S.; Vergotte, I.; Colombo, N.; Barve, M.; Grisham, R.; Mehr, K. T.; Falk, M.; Beier, F.; Hennessy, M.; Schroeder, A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • A phase II trial of durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial carcinoma and endometrial carcinosarcoma
    Meeting Abstract

    Rubinstein, M. M.; Caird, I.; Zhou, Q.; Iasonos, A.; Friedman, C. F.; Cadoo, K. A.; Konner, J. A.; O'Cearbhaill, R. E.; Tew, W. P.; Zamarin, D.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save